Last reviewed · How we verify
ROBO1 CAR-NK cells
At a glance
| Generic name | ROBO1 CAR-NK cells |
|---|---|
| Sponsor | Asclepius Technology Company Group (Suzhou) Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Research of ROBO1 Specific BiCAR-NK Cells on Patients With Pancreatic Cancer (PHASE1, PHASE2)
- Clinical Research of ROBO1 Specific CAR-NK Cells on Patients With Solid Tumors (PHASE1, PHASE2)
- Clinical Research of ROBO1 Specific BiCAR-NK/T Cells on Patients With Malignant Tumor (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ROBO1 CAR-NK cells CI brief — competitive landscape report
- ROBO1 CAR-NK cells updates RSS · CI watch RSS
- Asclepius Technology Company Group (Suzhou) Co., Ltd. portfolio CI